Analytical validation of a novel multi-analyte plasma test for lung nodule characterization.
Neil N Trivedi, James K Brown, Tess Rubenstein, Abigail D Rostykus, Amanda L Fish, Heng Yu, Luis Carbonell, Alice Juang, Sandy Kamer, Bhavin Patel, Manpreet Sidhu, Doris Vuong, Shan Wang, Mike Beggs, Alan Hb Wu, Mehrdad Arjomandi
Author Information
Neil N Trivedi: San Francisco Veterans Affairs Medical Center, USA.
James K Brown: San Francisco Veterans Affairs Medical Center, USA.
Tess Rubenstein: San Francisco Veterans Affairs Medical Center, USA.
Abigail D Rostykus: San Francisco Veterans Affairs Medical Center, USA.
Amanda L Fish: MagArray Inc, Milpitas, CA, USA.
Heng Yu: MagArray Inc, Milpitas, CA, USA.
Luis Carbonell: MagArray Inc, Milpitas, CA, USA.
Alice Juang: MagArray Inc, Milpitas, CA, USA.
Sandy Kamer: MagArray Inc, Milpitas, CA, USA.
Bhavin Patel: MagArray Inc, Milpitas, CA, USA.
Manpreet Sidhu: MagArray Inc, Milpitas, CA, USA.
Doris Vuong: MagArray Inc, Milpitas, CA, USA.
Shan Wang: MagArray Inc, Milpitas, CA, USA.
Mike Beggs: MagArray Inc, Milpitas, CA, USA.
Alan Hb Wu: University of California, San Francisco, USA.
Mehrdad Arjomandi: San Francisco Veterans Affairs Medical Center, USA.
BACKGROUND: In the National Lung Screening Trial, 96.4% of nodules had benign etiology. To avoid unnecessary actions and exposure to harm, individuals with benign disease must be identified. We describe herein the analytical validation of a multi-analyte immunoassay for characterizing the risk that a lung nodule found on CT is malignant. Those at lower risk may be considered for serial surveillance to avoid unnecessary and potentially harmful procedures. While those nodules characterized at higher risk may be appropriate for more aggressive actions. OBJECTIVE: To validate the analytical performance of multiplexed plasma protein assays used in a novel test for lung nodule characterization. METHODS: A multiplexed immunoassay panel for the measurement of plasma proteins in current smokers who present with a lung nodule on CT scan was evaluated in a clinical testing laboratory. Assay analytical sensitivity, reproducibility, precision, and recovery of Epidermal Growth Factor Receptor (EGFR), Prosurfactant protein B (ProSB), and Tissue Inhibitor of Metalloproteinases 1 (TIMP1) from human EDTA plasma samples were evaluated across multiple runs, lots, and technicians. Interfering substances and sample pre-analytical storage conditions were evaluated for their effect on analyte recovery. The lung nodule risk score reproducibility was assessed across multiple lots. RESULTS: The assay sensitivities were 0.10 ng/mL EGFR, 0.02 ng/mL ProSB, and 0.29 ng/mL TIMP1 with over three orders of magnitude in the assay dynamic ranges. The assays and analytes are robust to pre-analytical sample handling and the plasma can be stored for up to 4 days at 4°C either when freshy collected or thawed after long-term storage at -80°C. Total imprecision after 20 days of testing remained under 9% for all three assays. Risk score variability remained within a ± 10% risk score range. CONCLUSIONS: The three protein assays comprising the multi-analyte plasma test for lung nodule characterization performed quite acceptably in a clinical laboratory.
